Company Insights

QNRX supplier relationships

Explore interactive graphBrowse insights index
QNRX supplier relationship map

Quoin Pharmaceuticals (QNRX): Supplier relationships that shape an early-stage biotech investment

Quoin Pharmaceuticals develops topical and specialty formulations for rare dermatological diseases and monetizes through exclusive licensing, clinical development programs and capital markets transactions that fund that development. The company’s earnings profile is pre-revenue and capital-dependent: value is created through successful clinical milestones, regulatory exclusivity, and downstream licensing or commercial partnerships. Investors assessing supplier risk should focus on contracting posture (mix of long- and short-term research agreements), supplier concentration (single-source manufacturing and CRO exposure), and the company’s continued reliance on placement agents to access capital markets. Learn more at https://nullexposure.com/.

Why supplier relationships matter for QNRX investors

Quoin is not a revenue-generating manufacturer; it is a clinical-stage specialty pharma company whose operational continuity depends on a handful of external scientific and capital services. Clinical progress, not product sales, drives valuation, so vendors that provide R&D, manufacturing and financing services are functionally critical. The company’s public disclosures and press distribution show a pattern: strategic licensing for IP, multi-year academic research agreements, reliance on third-party manufacturers and CROs, and repeated use of boutique investment banks for capital raises.

Visit https://nullexposure.com/ for an investor-ready supplier risk overview.

Who Quoin works with (what the record shows)

Below are every named relationship captured in public press and filings in the supplied results, with a concise investor-facing description and a source citation.

Aegis Capital Corp.

Aegis Capital served as a co-placement agent on Quoin’s public offering, a role that directly supported the company’s 2023 equity raise and liquidity. Source: GlobeNewswire press release announcing the pricing of a $7.0 million public offering (Feb 22, 2023).

A.G.P. / Alliance Global Partners

A.G.P. acted as the lead placement agent on the same 2023 financing, which positions the firm as Quoin’s primary capital markets intermediary for that transaction. Source: GlobeNewswire press release on the Feb 22, 2023 public offering.

Maxim Group LLC

Maxim Group has acted both as a co-placement agent (2023) and later as the sole placement agent for private placements in FY2025, indicating an ongoing financing advisory relationship used to facilitate equity injections. Source: GlobeNewswire public offering notice (Feb 22, 2023) and a FY2025 private placement announcement on Yahoo Finance and other market sites.

PCG Advisory

PCG Advisory functions as Quoin’s investor relations contact across multiple press releases from FY2025–FY2026, handling external communications tied to clinical and regulatory milestones. Source: multiple press releases distributed via GlobeNewswire and Yahoo Finance that list PCG Advisory as investor relations (FY2025–FY2026).

GlobeNewswire

GlobeNewswire is the distributor of Quoin’s press releases, and it has been used to disseminate both financing and regulatory milestone announcements, including the public offering notice and orphan designation press releases. Source: GlobeNewswire distributions covering the Feb 22, 2023 offering and the Oct 21, 2025 FDA orphan designation announcement.

What the constraints reveal about Quoin’s operating model

The company disclosures and contract excerpts deliver a consistent set of company-level signals that shape supplier risk and operational resilience.

  • Contracting posture and maturity: Quoin uses a mix of long-term master agreements and finite research contracts. The company disclosed a three-year initial term with automatic one-year extensions for both an MSA with Therapeutics Inc. and an early UCC research agreement, illustrating multi-year commitments with embedded renewal mechanics rather than purely transactional procurement.

  • R&D-focused spend and lifecycle timing: Research agreements with academic partners have defined milestone payments and timelines: the UCC arrangement includes up to roughly €567,000 over an anticipated 2.5-year period, and QUT agreements were initially anticipated to be ~18 months. These arrangements indicate predictable mid-term cash outflows tied to development milestones, not indefinite retainers.

  • Licensing and intellectual property position: Quoin is a licensee under an exclusive, royalty-bearing agreement with Skinvisible Pharmaceuticals for QRX003 and QRX004. That licensing posture locks IP rights into the company’s development pathway and creates downstream royalty obligations should commercialization occur.

  • Supplier concentration and single-source risk: Disclosure confirms dependency on several third parties, including single-source suppliers for API and contract manufacturing, and a CRO managing both clinical studies. That concentration constitutes high operational criticality because a single vendor failure could delay multiple programs.

  • Service provider roles: The company outsources formulation, preclinical and clinical work to academic and commercial partners (QUT, UCC, others) and uses external providers for non-core services such as payroll and IT, implying broad vendor reliance across both R&D and corporate functions.

  • Geographic footprint and trial expansion: Quoin’s clinical strategy is international — sites in the U.S., Ireland, New Zealand and plans for the Middle East, UK and European expansion — which increases regulatory and supply chain complexity but diversifies patient recruitment risk.

  • Spending scale on near-term studies: An amended change order in late 2024 quantified roughly $3.6 million in remaining costs for two studies, placing near-term development spending in the $1m–$10m band and underscoring capital needs to complete pivotal work.

  • Relationship stage and activity: QRX003 is in active clinical testing under an open IND with the FDA, which means supplier commitments currently have operational consequences rather than theoretical exposures.

Place a supplier risk review request or benchmark Quoin against peers at https://nullexposure.com/.

Investment implications: risks and levers

  • Capital dependency is the immediate financial risk: Quoin is pre-revenue and uses boutique placement agents (Maxim, A.G.P., Aegis) as a recurring pathway to liquidity. Investors should monitor runway and the cadence of placement-agent-led financings as a leading indicator of execution ability.
  • Operational concentration on single-source API and CRO suppliers is a material program risk; any disruption can delay clinical milestones and devalue licensing optionality.
  • Licensing locks with Skinvisible grant Quoin exclusive development rights but create long-term royalty obligations that will affect future margins if commercialized.
  • Geographic expansion de-risks recruitment but increases operational and regulatory costs; investors should weigh trial-site diversification against supply-chain fragility.

Bottom line and next steps

Quoin Pharmaceuticals operates a classic clinical-stage biotech model: value driven by clinical milestones, financed through equity placements, and executed via a network of research, manufacturing and communications vendors. Key watch items for operators and investors are supplier concentration, financing cadence, and milestone funding commitments.

For a focused supplier exposure assessment and peer comparison, start at https://nullexposure.com/. For tailored due diligence on Quoin’s vendor risk and contract posture, the platform provides actionable signals for investment and operational decision-making.